Export 37 results:
Author Title [ Type(Desc)] Year
Filters: Author is Hill, Heather  [Clear All Filters]
Journal Article
F. M. Munoz, Weisman, L. E., Read, J. S., Siberry, G., Kotloff, K., Friedman, J., Higgins, R. D., Hill, H., Seifert, H., and Nesin, M., Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy., Clin Infect Dis, vol. 59 Suppl 7, pp. S415-27, 2014.
L. Lai, Rouphael, N., Xu, Y., Sherman, A. C., Edupuganti, S., Anderson, E. J., Lankford-Turner, P., Wang, D., Keitel, W., McNeal, M. M., Cross, K., Hill, H., Bellamy, A. R., and Mulligan, M. J., Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine., Vaccines (Basel), vol. 8, no. 1, 2020.
I. N. Mbawuike, Atmar, R. L., Patel, S. M., Corry, D. B., Winokur, P. L., Brady, R. C., Chen, W. H., Edwards, K. M., C Creech, B., Walter, E. B., Frey, S. E., Belshe, R. B., Goll, J. B., Hill, H., and Keitel, W. A., Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine., Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
L. M. Howard, Hoek, K. L., Goll, J. B., Samir, P., Galassie, A., Allos, T. M., Niu, X., Gordy, L. E., C Creech, B., Prasad, N., Jensen, T. L., Hill, H., Levy, S. E., Joyce, S., Link, A. J., and Edwards, K. M., Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial., PLoS One, vol. 12, no. 1, p. e0167488, 2017.
K. L. Kotloff, Halasa, N. B., Harrison, C. J., Englund, J. A., Walter, E. B., King, J. C., C Creech, B., Healy, S. A., Dolor, R. J., Stephens, I., Edwards, K. M., Noah, D. L., Hill, H., and Wolff, M., Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children., Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
S. E. Frey, Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. El, El-Kamary, S. S., Edwards, K., Keyserling, H., Winokur, P., Keitel, W., Hill, H., Goll, J. B., Anderson, E. L., Graham, I. L., Johnston, C., Mulligan, M., Rouphael, N., Atmar, R., Patel, S., Chen, W., Kotloff, K., C Creech, B., Chaplin, P., and Belshe, R. B., Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects., Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
R. W. Frenck, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults., Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
R. L. Atmar, Opekun, A. R., Gilger, M. A., Estes, M. K., Crawford, S. E., Neill, F. H., Ramani, S., Hill, H., Ferreira, J., and Graham, D. Y., Determination of the 50% human infectious dose for Norwalk virus., J Infect Dis, vol. 209, no. 7, pp. 1016-22, 2014.
S. M. Patel, Atmar, R. L., Sahly, H. M. El, Guo, K., Hill, H., and Keitel, W. A., Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes., J Infect Dis, vol. 206, no. 7, pp. 1069-77, 2012.
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial., JAMA, vol. 314, no. 3, pp. 237-46, 2015.
D. I. Bernstein, Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K. B., Graham, I. L., Noah, D. L., He, F., and Hill, H., Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults., J Infect Dis, vol. 197, no. 5, pp. 667-75, 2008.
S. E. Frey, Stapleton, J. T., Ballas, Z. K., Rasmussen, W. L., Kaufman, T. M., Blevins, T., Jensen, T. L., D Davies, H., Tary-Lehman, M., Chaplin, P., Hill, H., and Goll, J. B., Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses., J Infect Dis, 2021.
N. Ali Goji, Nolan, C., Hill, H., Wolff, M., Noah, D. L., Williams, T. B., Rowe, T., and Treanor, J. J., Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant., J Infect Dis, vol. 198, no. 5, pp. 635-41, 2008.
P. Winokur, Sahly, H. M. El, Mulligan, M. J., Frey, S. E., Rupp, R., Anderson, E. J., Edwards, K. M., Bernstein, D. I., Schmader, K., Jackson, L. A., Chen, W. H., Hill, H., and Bellamy, A., Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older., Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
D. I. Bernstein, Jackson, L., Patel, S. M., Sahly, H. M. El, Spearman, P., Rouphael, N., Rudge, T. L., Hill, H., and Goll, J. B., Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults., Vaccine, vol. 32, no. 47, pp. 6284-93, 2014.
L. A. Jackson, Chen, W. H., Stapleton, J. T., Dekker, C. L., Wald, A., Brady, R. C., Edupuganti, S., Winokur, P., Mulligan, M. J., Keyserling, H. L., Kotloff, K. L., Rouphael, N., Noah, D. L., Hill, H., and Wolff, M. C., Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons., J Infect Dis, vol. 206, no. 6, pp. 811-20, 2012.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
S. L. Hillier, Ferrieri, P., Edwards, M. S., Ewell, M., Ferris, D., Fine, P., Carey, V., Meyn, L., Hoagland, D., Kasper, D. L., Paoletti, L. C., Hill, H., and Baker, C. J., A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III., Clin Infect Dis, vol. 68, no. 12, pp. 2079-2086, 2019.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals., Vaccine, vol. 32, no. 23, pp. 2732-9, 2014.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations., Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
E. J. Anderson, Lai, L., Wrammert, J., Kabbani, S., Xu, Y., Priyamvada, L., Hill, H., Goll, J. B., Jensen, T. L., Kao, C., Yildirim, I., Rouphael, N., Jackson, L., and Mulligan, M. J., Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine., Vaccines (Basel), vol. 8, no. 1, 2020.
D. F. Hoft, Lottenbach, K., Goll, J. B., Hill, H., Winokur, P. L., Patel, S. M., Brady, R. C., Chen, W. H., Edwards, K., C Creech, B., Frey, S. E., Blevins, T. P., Salomon, R., and Belshe, R. B., Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination., J Infect Dis, vol. 214, no. 7, pp. 1020-9, 2016.
A. C. Galassie, Goll, J. B., Samir, P., Jensen, T. L., Hoek, K. L., Howard, L. M., Allos, T. M., Niu, X., Gordy, L. E., C Creech, B., Hill, H., Joyce, S., Edwards, K. M., and Link, A. J., Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination., Proteomics, vol. 17, no. 12, 2017.
D. L. Noah, Hill, H., Hines, D., E White, L., and Wolff, M. C., Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure., Clin Vaccine Immunol, vol. 16, no. 4, pp. 558-66, 2009.
T. L. Jensen, Frasketi, M., Conway, K., Villarroel, L., Hill, H., Krampis, K., and Goll, J. B., RSEQREP: RNA-Seq Reports, an open-source cloud-enabled framework for reproducible RNA-Seq data processing, analysis, and result reporting., F1000Res, vol. 6, p. 2162, 2017.